CDK4/6 inhibitors in HR-positive breast cancer immunotherapy

Breast cancer is the most prevalent malignant tumour among women. Approximately 70 % of patients are hormone receptor (HR)-positive and undergo endocrine therapy as the main form of treatment; however, the efficacy of this type of therapy is limited by some factors, such as drug resistance and complex tumour microenvironments. Using network pharmacology and molecular docking, this study examined how CDK4/6 inhibitors enhance the effects of immunotherapy for HR-positive breast cancer, focusing on their effects on the tumour microenvironment (TME) and immune cell activity. CDK4/6 inhibitor influence crucial signalling pathways, including TP53 and EGFR, underscoring their importance in modulating immune responses and combating drug resistance. Our analysis revealed that the combination of CDK4/6 inhibitors with other immunotherapies, such as immune checkpoint inhibitors, might play an important role in improving the effectiveness of treatment in patients with cancer. This study provides new perspectives on treatment options for HR-positive breast cancers, promoting ongoing research and improvements in therapeutic approaches.